A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes Mellitus and End-Stage Renal Disease Who Are on Dialysis and Who Have Inadequate Glycemic Control
- Registry ID
- EUCTR2007-003529-26
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- Merck & Co., Inc.
- Start date
- 2007-10-31
- Completion date
- 2011-03-14
- Last update
- 2026-08-16
Conditions
- Type II Diabetes mellitus
Summary
After 54 weeks, to assess the effect (change from baseline) of sitagliptin on HbA1c; After 54 weeks, to assess the safety and tolerability of sitagliptin.
Locations
View on source registry